Patients received anti-TNF-α treatment due to 226 (50.4%) ankylosing spondylitis, 160 (35.7%) RA, 54 (12.1%) psoriatic arthritis, and 8 (1.8%) Behçet's disease. This evidence concerns the gene TNF and psoriatic arthritis.